Educational guide
Are Research Peptides Legal?
"Legal" means something different depending on which peptide you're talking about, what it's being used for, and how it's being sold. The peptide landscape in 2026 is more complicated than it was three years ago, and, whether you're a researcher, a clinician,
This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.
"Legal" means something different depending on which peptide you're talking about, what it's being used for, and how it's being sold. The peptide landscape in 2026 is more complicated than it was three years ago, and, whether you're a researcher, a clinician, or someone exploring peptide therapies for personal use, it's good practice to understand what's going on in the legal space.
Most peptides exist in a layered regulatory framework where legality depends on the combination of the compound itself, its intended use, and the legal category it falls into under federal law.
For instance, some peptides are FDA-approved drugs. Some can be legally compounded by licensed pharmacies under certain conditions. Some are sold legally as research-only compounds with labeling that reflects that status. And some are outright prohibited from being marketed for human consumption in the United States.
This article is for educational purposes only and isn't intended to provide legal advice. The peptide space is constantly evolving, so while we'll continue to update this blog post regularly, some of what's reflected here may not be the most current regulatory news.
FDA-Approved Peptide Drugs: The Clearest Legal Category
Some of the most widely used drugs in medicine right now are peptides or peptide-based drugs.
Insulin, the foundational treatment for diabetes, is a peptide hormone. Semaglutide, the active compound in Ozempic and Wegovy, is a GLP-1 receptor agonist peptide that has become one of the most prescribed drugs in the country.
Another common peptide drugs are oxytocin (used in obstetric care) and triptorelin, used in hormone-related cancer treatments. These are all FDA-approved peptide drugs that have completed full clinical trials, received regulatory approval, and carry an established safety and efficacy profile for their approved indications.
FDA-approved peptide drugs are legal for human use when prescribed by a licensed healthcare provider for approved indications. The approval status covers not just the compound but the specific formulation, dose, and delivery method that was studied in clinical testing. That's a meaningful distinction when it comes to compounding, which we'll get to shortly.
Growth hormone and growth hormone-related peptides live in a specific regulatory position worth noting. Human growth hormone (somatropin) is an FDA-approved drug for specific indications including growth hormone deficiency. Growth hormone secretagogues, the class of peptides that stimulate the body's own growth hormone production, are in a more complex regulatory territory and have been significantly affected by FDA's recent actions on compounding.
Pharmacy Compounding and the Bulk Drug Substances List
Compounding pharmacies prepare customized medications for individual patients when a commercially available drug doesn't meet a specific clinical need, for example, a different dose, a different delivery form, or the removal of an ingredient a patient is allergic to. Legal compounding operates under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, and the FDA regulates which bulk drug substances can be used in this process [1] .
This is where things get more complicated for the peptide landscape starting in 2023 and 2024. The FDA took explicit regulatory action on the bulk drug substances list for peptides, dividing them into categories that determine whether they can or can't be compounded.
Category 1 Peptides
Category 1 is the only bucket where FDA has allowed interim use.
Category 1 peptides are substances that were nominated with sufficient information and did not raise immediate "do not use" red flags. These are still under evaluation, but FDA has stated it doesn't intend to take enforcement action against 503A pharmacies or 503B outsourcing facilities that compound with Category 1 substances, as long as all other legal and quality requirements are met.
Examples of peptides that can be Category 1 in certain contexts include those that either have a USP monograph, are components of an FDA-approved drug, or have been nominated with adequate safety and quality data (for example, sermorelin when used in compliant ways). Category 1 means "under review but currently allowed," not "banned."
Category 2 Peptides
Category 2 is where the high-profile wellness peptides have landed.
FDA's policy has been that 503A and 503B compounders should not use Category 2 substances, and the agency may take enforcement action if they do [2] .
In late 2023 and into 2024, FDA placed a number of popular wellness and sports-medicine peptides into Category 2 for 503A/503B purposes, including:
BPC-157
CJC-1295
Ipamorelin
TB-500 (thymosin beta-4 fragment)
GHK-Cu for injectable routes
Melanotan II and several others
Compounding pharmacies that had been preparing BPC-157, CJC-1295, ipamorelin, TB-500, and similar peptides for patient-specific prescriptions under wellness-clinic or telehealth oversight are no longer operating in legal compliance if they continue to use these substances as bulk drugs for human preparations.
By contrast, some peptides like sermorelin can qualify for compounding when they have a USP monograph or appear on the 503A bulks list, while FDA-approved peptides such as bremelanotide (PT-141) face additional restrictions and are not simply "Category 2" in the same way as BPC-157 or CJC-1295.
Category 3 Peptides
Category 3 substances are those that were nominated for the bulks list with insufficient supporting information for FDA to properly evaluate them. They might turn out to be acceptable or unacceptable, but the nomination didn't include enough data (on safety, quality, or use) for FDA to make that call.
At one point, GHRP-2 (a GH-releasing peptide) was listed as Category 3 on the interim 503A bulks list, meaning there wasn't enough information for FDA to allow its use under enforcement discretion.
Later revisions moved GHRP-2 to Category 1 for certain non-injectable routes, while it remained restricted for injectable use — showing how FDA can reclassify a peptide as more data and route-specific risk information become available.
That kind of example shows categories are regulatory tools, not permanent labels. Category 3 means "no go for compounding right now because the evidence isn't there," and only if a substance is re-evaluated and shifted into Category 1 for specific routes does interim compounding become legally possible.
Research-Only Peptides: Legal to Buy and Sell, With Important Conditions
Research peptides occupy a distinct legal category that's often misunderstood. They're not in a legal gray area, they're in a specific defined category: compounds that can be legally manufactured, sold, and purchased in the United States as long as they're labeled for research use only and not marketed for human use or human consumption.
The FDA's position on research-only peptides is that they are not approved drugs, and they can't be sold as drugs, dietary supplements, or food products. But selling them as research chemicals with appropriate labeling, including explicit statements that they're not intended for human use, does not by itself violate federal law.
What does violate federal law is when a vendor markets a research peptide in ways that imply it's intended for human use.
That means no therapeutic claims, no dosing guidance framed for patients, no before-and-after testimonials about health outcomes. The "not for human use" is the legal basis on which these compounds can be sold.
Vendors who maintain that distinction clearly are operating within the framework. Those who don't, by making implied clinical claims or structuring their marketing around patient outcomes, are creating safety risks and significant legal exposure.
The compound itself isn't illegal to purchase. But if you're purchasing it for personal use rather than actual research, you're operating outside the intended use framing that governs the legal sale. That doesn't make the purchase illegal in most circumstances, but it does mean you're using a compound without the FDA approval status, quality oversight, and dosing guidance that would apply to an approved drug.
Peptide Legal Status at a Glance
Here's how the major categories of peptides map to their current legal status in the United States. For each, the examples, the legal status for human use, and whether it can be compounded for humans:
FDA-approved peptide drugs
Examples: Semaglutide (Ozempic), insulin, oxytocin, bremelanotide (PT-141).
Legal status (human use): Approved as prescription drugs for specific labeled indications.
Can be compounded for humans? Only in narrow circumstances (e.g., certain shortages or specific, justified clinical need); otherwise use approved product.
Category 1 bulk substances (under evaluation, allowed with conditions)
Examples: Peptides that meet at least one legal criterion (e.g., sermorelin with USP monograph or other qualifying context).
Legal status (human use): Nominated with sufficient data; under review but currently allowed under FDA's Category 1 enforcement discretion.
Can be compounded for humans? Yes, if all 503A/503B conditions are met and the substance is in Category 1 for the relevant route.
Category 2 bulks (significant safety concerns — not allowed)
Examples: BPC-157, CJC-1295, ipamorelin, TB-500, injectable GHK-Cu, Melanotan II.
Legal status (human use): FDA identified significant safety/other concerns; these substances do not meet legal criteria for bulk use under 503A/503B.
Can be compounded for humans? No. 503A pharmacies and 503B outsourcing facilities are not supposed to compound with Category 2 substances for human use.
Category 3 bulks (insufficient information — not allowed)
Examples: Peptides and other substances nominated without adequate supporting data (e.g., some GH secretagogues before reclassification).
Legal status (human use): Nominated with insufficient information for FDA to evaluate; not eligible for Category 1 enforcement discretion.
Can be compounded for humans? No. FDA may take action if 503A/503B compounders use Category 3 substances in human preparations.
Research-only peptides (lab reagents, not drugs)
Examples: Catalog BPC-157, TB-500, GHK-Cu, "RUO" versions of many peptides.
Legal status (human use): Often sold as "for research only, not for human use"; not FDA-approved drugs and not part of 503A/503B bulks.
Can be compounded for humans? N/A for legal human compounding; using these in people falls outside the regulated compounding/approved-drug systems.
Cosmetic peptides (topical use)
Examples: GHK-Cu serums, cosmetic copper peptide creams.
Legal status (human use): Legal as cosmetic ingredients when used within cosmetic regulations (no drug claims, appropriate concentrations, etc.).
Can be compounded for humans? N/A in the 503A/503B sense; they are regulated under cosmetic, not prescription-drug, frameworks.
All of this is US-specific and for human drug compounding. Veterinary rules are different, and inclusion in a category does not mean FDA "approves" a substance — only that it may or may not be eligible to be used as a bulk ingredient under compounding law.
How the Regulatory Environment Has Been Shifting
In the United States, one of the biggest changes has been around compounded peptides — the ones mixed by 503A/503B compounding pharmacies for human use with a prescription.
Starting in 2023, the FDA updated its "bulks lists," which are the ingredient lists that decide what these pharmacies can legally use. Several well-known wellness peptides, including BPC-157, CJC-1295, ipamorelin, TB-500, and some injectable GHK-Cu products, were placed into Category 2.
Category 2 is basically the "red flag" bucket: FDA says these substances have significant safety or other concerns and should not be used as bulk ingredients in human drug compounding.
For clinics and wellness centers that were getting these peptides from licensed pharmacies, this was a big shift. Pharmacies that keep compounding Category 2 peptides for people are now operating outside FDA's current guidance, which is why many of those products have disappeared from legitimate compounding channels.
How The Industry Has Pushed Back
Not surprisingly, the compounding and wellness communities haven't loved this.
Groups like the Alliance for Pharmacy Compounding argue that FDA's approach doesn't reflect how some clinicians were using these peptides in practice, especially in areas like injury recovery or longevity where there are few approved options.
They've been lobbying for FDA to revisit certain decisions, and some pharmacy-law groups have talked about legal challenges and ongoing policy fights. But as of mid-2025, the FDA's core decisions — especially the Category 2 status for peptides like BPC-157 and CJC-1295 — are still in place.
What This Means If You're Buying "Research Peptides"
If a peptide can't legally be compounded for humans, but you still see it for sale online, it's usually being sold as a "research-only" product, but it's not an FDA-approved drug.
Those products sit outside the normal pharmacy system. That often means less oversight of purity, sterility, dose accuracy, and long-term safety than you'd get with an FDA-approved medication or a legally compounded prescription.
That doesn't mean every research peptide bottle is automatically fake or harmful — but it does mean you're no longer in the same regulated world as a prescription filled at a licensed pharmacy.
State-by-State Considerations
Federal law sets the baseline, but state pharmacy boards and state medical licensing boards have their own regulatory framework that affects how peptide therapies are available in practice. So even though the core peptide rules are federal, how aggressively they are enforced can look different from state to state.
There isn't an official public ranking of "strict vs. loose" peptide states, and formal data are limited.
Some states take a very hands-on approach to compounding pharmacy oversight. Pharmacies in those states tend to be more cautious and will often stop making a peptide as soon as FDA signals a concern. In other states, enforcement is slower or less visible, and some compounders continue operating in regulatory gray areas until a board or the FDA steps in.
Telehealth clinics and online peptide programs have exploded in the last few years. The catch is that they have to follow two sets of rules at once: federal rules about what can legally be compounded, and state-specific rules about who can prescribe what over telehealth. That means a peptide protocol that's routine in one state might be off-limits or higher-risk for prescribers in another.
Topical and Cosmetic Peptides: A Different Legal Framework
Peptides used in skincare and topical applications operate under the cosmetic framework of the Federal Food, Drug, and Cosmetic Act, rather than the drug framework. This is a meaningful distinction.
A copper peptide serum containing GHK-Cu, for example, is regulated as a cosmetic.
Cosmetics don't require pre-market FDA approval, but they can't make drug claims, meaning they can't claim to treat, cure, or prevent any condition. The legal distinction between a cosmetic claim ("supports skin firmness") and a drug claim ("treats aging skin") is what keeps topical peptide products in the cosmetic framework. Cross that line, and the product is treated as an unapproved drug.
This framework is why topical GHK-Cu products are available in mainstream retail channels while injectable GHK-Cu sits in the research-only category. Same compound, different delivery, different regulatory framework, different legal status.
What This Means for Researchers and Consumers
If you're a researcher using peptides for legitimate research purposes, the legal framework is relatively straightforward.
Research-only peptides can be purchased from vendors who maintain RUO labeling and don't market them for human use. Your institutional context, any IRB requirements, and the specific compound's research-use documentation are the relevant considerations.
If you're exploring stabilized non-injectable peptide formats, like nasal sprays or stabilized tablet formulations sold as research compounds, you're in the research-only category. That means the purchase is legal under RUO labeling, but you're using a compound without clinical trial data, FDA approval status, or the quality oversight of pharmaceutical manufacturing.
The immune reactions and safety risks associated with unapproved peptides are real, particularly for injectable forms prepared outside pharmaceutical-grade manufacturing. Immune response to contaminants in poorly manufactured peptides, injection site complications from non-sterile preparation, and dosing errors from mislabeled compounds are the documented safety concerns that drive the FDA's regulatory position. These risks are lower for stabilized non-injectable formats from vendors with documented third-party quality testing, but they don't disappear entirely.
References
Jackson, L. M., Parker, R. M., Mattison, D. R., & National Academies of Sciences, Engineering, and Medicine. (2020). Regulatory framework for compounded preparations. In The Clinical Utility of Compounded Bioidentical Hormone Therapy: A Review of Safety, Effectiveness, and Use. National Academies Press (US).
US Food and Drug Administration. (2024). Bulk Drug Substances Used in Compounding Under Section 503B of the FD&C Act.